Drug General Information
Drug ID
D04KHX
Former ID
DCL000135
Drug Name
INCB3284
Drug Type
Small molecular drug
Indication Obese insulin-resistant disorders; Rheumatoid arthritis [ICD9: 250, 710-719, 714; ICD10:E11, M05-M06] Discontinued in Phase 2 [547666]
Company
Incyte
Structure
Download
2D MOL

3D MOL

Formula
CH6N4
Canonical SMILES
C(=NN)(N)N
InChI
1S/CH6N4/c2-1(3)5-4/h4H2,(H4,2,3,5)
InChIKey
HAMNKKUPIHEESI-UHFFFAOYSA-N
CAS Number
CAS 17617-45-7
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) C-C chemokine receptor type 2 Target Info Antagonist [550211]
KEGG Pathway Cytokine-cytokine receptor interaction
Chemokine signaling pathway
NetPath Pathway TCR Signaling Pathway
IL2 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
Leptin Signaling Pathway
RANKL Signaling Pathway
PANTHER Pathway Inflammation mediated by chemokine and cytokine signaling pathway
Reactome Beta defensins
Chemokine receptors bind chemokines
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Defensins
Spinal Cord Injury
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 547666Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018258)
Ref 550211Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients. Incyte Corporation. 2005.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.